by Zhao, Y. et al.
Department of Medicine, University of British Columbia, Vancouver, Canada
Department of Medicine, University of British Columbia, Vancouver, Canada
Placebo relapsing-remitting multiple sclerosis patients experience a decline of new gadolinium activity over 9 months.
Neurology. 2008; 13 Pt 2:1092-7